About this Research Topic
The concept of using RNA as a therapeutic tool dates back some 30 years. Coming from a slow start, this vaccine platform has benefited in recent years from numerous technological improvements. Its capacity to induce robust humoral and cellular immune responses and protection in model systems, and its potential for rapid industrial production following recent advances associated with the COVID-19 pandemic has made it a promising vaccine platform. However, clinical experience with RNA vaccines was limited until recent studies of SARS-CoV2 vaccine candidates with promising results now obtained in Phase 3 trials of two different RNA vaccine candidates. While the efficacy obtained with these vaccines appears to be remarkable, long-term efficacy and tolerability remain unknown.
In this Research Topic, we propose to cover the current status of RNA vaccination approaches in the context of infectious diseases.
We welcome the submission of Mini Review, Review, Original Research, Perspective and Methods articles covering, but not limited to, the following sub-topics:
- Pharmaceutical or technological developments focusing on improvements to the RNA vaccine platform
- In vitro effects of RNA vaccines
- In vivo effects of RNA vaccines, including persistence and targeted cells
- Results from preclinical studies or clinical trials focusing on infectious diseases
- Prospects for use in the context of infectious diseases
Keywords: SARS-CoV-2, Vaccine, RNA Vaccine, COVID-19
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.